Efficacy of surufatinib in advanced Grade 3 neuroendocrine tumors: a real-world, national, multicenter study

Jian Wang, Ning Zhang, Yun Liang, Jiang Long, Yihebali Chi, Suzhen Zhang, Chunmei Bai, Yu Wang, Yinying Wu, Hanguang Hu, Weiyu Hu, Li Huang, Ying Liu, Huifang Lv, Shanai Song, Aili Suo, Xiangling Wang, Lin Zhang, Liming Zhu, Jie Chen, Jing Hao

Therapeutic Advances in Medical Oncology

Published online on July 31, 2026

Abstract

Therapeutic Advances in Medical Oncology, Volume 18, January-December 2026.
Background:Well-differentiated Grade 3 neuroendocrine tumors (G3 NETs) represent a heterogeneous entity with limited therapeutic standards. Surufatinib, a small-molecule inhibitor, has shown efficacy in G1/G2 NETs, but its specific role in the G3 ...